Design Therapeutics, Inc. DSGN

12.12 (0.24) (1.94%) as of 25 Sep
Market cap
$809.3M
P/E
0.0×
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 — — — — —
P/S ratio
— — 2,377.24 — — — — —
P/FCF ratio
— — 0.00 — — — — —
P/Operating CF
— — (188.91) — — — — —
P/B ratio
— — 0.00 — — — — —
Price to Tangible BV
— — 0.00 — — — — —
EV/Sales
— — 2,217.54 — — — — —
EV/EBITDA
— — 0.00 — — — — —
EV/Operating CF
— — (57.81) — — — — —
EV/FCF
— — (57.81) — — — — —
Quick Ratio
— 0.02 15.49 72.70 30.66 29.29 29.01 16.84
Current Ratio
— 0.02 15.55 72.96 31.10 29.58 29.31 17.14
Net Debt/EBITDA
— (0.23) 4.30 10.73 4.82 3.37 3.61 2.68
Debt/Assets
0.00% 772.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— (0.19) 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.07 1.05 0.83 0.81 0.88 0.87 0.78
Capex/Depreciation
— — 1.15 (29.58) 0.89 0.05 0.06 0.07
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 27.37% 110.72% (19.16%) (17.85%) (22.10%) (19.08%) (30.70%)
ROA
— (4,548.89%) (45.24%) (16.64%) (17.30%) (21.20%) (18.31%) (29.18%)
ROIC
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— 56.22% (24.37%) (9.31%) (19.40%) (24.17%) (20.58%) (32.97%)
Average Days of Receivables
— — 0.00 0.00 0.00 — — —
Research and Development Expense of Revenue
— 0.00% 2,681.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 0.00% 1,104.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— — 199.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
— — (0.02) — — — — —
Graham Number
— — 2.91 — — — — —
Earnings Yield
— — (1.54%) — — — — —
Free Cash Flow Yield
— — (1.61%) — — — — —
Revenue per Share
— 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
— 0.00 (0.55) (0.64) (0.92) (1.05) (0.76) (0.95)
Capex per Share
— 0.00 0.00 (0.03) (0.02) 0.00 (0.01) 0.00
Free Cash Flow per Share
— 0.00 (0.55) (0.67) (0.94) (1.05) (0.77) (0.95)
Cash per Share
— 0.00 2.28 8.36 5.93 5.03 4.34 3.83
Shareholders Equity per Share
— (0.07) (0.72) 8.32 5.88 4.96 4.28 3.71
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (0.07) (0.72) 8.32 5.88 4.96 4.28 3.71
Free Cash Flow
— (0.14) (8.74) (30.91) (52.20) (58.82) (43.44) (54.55)
Working Capital
— (3.64) 33.90 380.15 324.34 274.96 239.58 210.73
Capital Expenditures
— — (0.08) (1.54) (0.88) (0.26) (0.34) (0.19)
Net Current Asset Value
— (3.64) (11.60) 377.01 321.29 272.63 238.04 210.08
EV/EBIT
— — 0.00 — — — — —
Capex to Sales
— — 0.34 0.00 0.00 0.00 0.00 0.00
Net Profit Margin
— 0.00% (3,663.72%) 0.00% 0.00% 0.00% 0.00% 0.00%
Price to Operating Income
— — 0.00 — — — — —
Other line items
Depreciation/Fixed assets
— — (0.93) 0.03 (0.51) (3.28) (3.97) (2.68)
Cash ROIC
— 4.84% (35.28%) (4.03%) (8.10%) (10.77%) (9.13%) (12.80%)
Accounts Receivable Turnover
— — 3.77 0.00 0.00 — — —
Accounts Payable Turnover
— — 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — 0.00 0.00 0.00 — — —
Average Days of Payables
— — 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — 0.00 0.00 0.00 — — —
Average Receivables
— — 0.06 0.06 0.61 — — —
Average Payables
— — 1.51 1.51 2.32 2.48 2.06 2.25
Average Assets
— 0.05 18.30 213.54 365.85 315.39 270.87 239.15
Average Common Equity
— (7.48) (7.48) 185.41 354.72 302.50 259.89 227.30

Fold the line items

Columns are period end dates